26 March 2026
26 March 2026
IntraSight Plus merges Philips’ technologies, offering co-registration, iFR/FFR physiology, and real-time device visualisation.
The Phase Ib trial will enrol around 54 patients to study cemsidomide with elranatamab and dexamethasone.
The partnership will combine Daiichi Sankyo’s clinical trial and preclinical research data with Tempus’ real-world data.
Achieving MDR compliance shows Modius Sleep meets safety, clinical, and quality standards required for entry into the EU market.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
